Jaap Verweij

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
de Bruijn Peter; Moghaddam-Helmantel Inge M Ghobadi; de Jonge Maja J A; Meyer Thorsten; Lam Mei-Ho; Verweij Jaap; Wiemer Erik A C; Loos Walter J
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
Mom Constantijne H; Verweij Jaap; Oldenhuis Corina N A M; Gietema Jourik A; Fox Norma Lynn; Miceli Renée; Eskens Ferry A L M; Loos Walter J; de Vries Elisabeth G E; Sleijfer Stefan
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Eskens Ferry A L M; Steeghs Neeltje; Verweij Jaap; Bloem Johan L; Christensen Olaf; van Doorn Leni; Ouwerkerk Jan; de Jonge Maja J A; Nortier Johan W R; Kraetzschmar Joern; Rajagopalan Prabhu; Gelderblom Hans
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jaap Verweij (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: de Bruijn Peter; Moghaddam-Helmantel Inge M Ghobadi; de Jonge Maja J A; Meyer Thorsten; Lam Mei-Ho; Verweij Jaap; Wiemer Erik A C; Loos Walter J
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;50(5):977-82.
2009: Mom Constantijne H; Verweij Jaap; Oldenhuis Corina N A M; Gietema Jourik A; Fox Norma Lynn; Miceli Renée; Eskens Ferry A L M; Loos Walter J; de Vries Elisabeth G E; Sleijfer Stefan
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5584-90.
2009: Eskens Ferry A L M; Steeghs Neeltje; Verweij Jaap; Bloem Johan L; Christensen Olaf; van Doorn Leni; Ouwerkerk Jan; de Jonge Maja J A; Nortier Johan W R; Kraetzschmar Joern; Rajagopalan Prabhu; Gelderblom Hans
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4169-76.
2009: Le Cesne Axel; Van Glabbeke Martine; Verweij Jaap; Casali Paolo G; Findlay Michael; Reichardt Peter; Issels Rolf; Judson Ian; Schoffski Patrick; Leyvraz Serge; Bui Binh; Hogendoorn Pancras C W; Sciot Raf; Blay Jean-Yves
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3969-74.
2009: Konings Inge R H M; Engels Frederike K; Sleijfer Stefan; Verweij Jaap; Wiemer Erik A C; Loos Walter J
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
Cancer chemotherapy and pharmacology 2009;64(3):509-16.
2009: Sleijfer Stefan; Ray-Coquard Isabelle; Papai Zsuzsa; Le Cesne Axel; Scurr Michelle; Schöffski Patrick; Collin Françoise; Pandite Lini; Marreaud Sandrine; De Brauwer Annick; van Glabbeke Martine; Verweij Jaap; Blay Jean-Yves
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3126-32.
2009: Kitzen J J E M; de Jonge M J A; Lamers C H J; Eskens F A L M; van der Biessen D; van Doorn L; Ter Steeg J; Brandely M; Puozzo Ch; Verweij J
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2009;45(10):1764-72.
2009: Baird Richard D; Kitzen Jos; Clarke Paul A; Planting Andre; Reade Sarah; Reid Alison; Welsh Lyndsey; López Lázaro Luis; de las Heras Begona; Judson Ian R; Kaye Stan B; Eskens Ferry; Workman Paul; deBono Johann S; Verweij Jaap
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Molecular cancer therapeutics 2009;8(6):1430-7.
2009: Konings I R H M; Verweij J; Wiemer E A C; Sleijfer S
The applicability of mTOR inhibition in solid tumors.
Current cancer drug targets 2009;9(3):439-50.
2009: Sleijfer S; Verweij J
The price of success: cost-effectiveness of molecularly targeted agents.
Clinical pharmacology and therapeutics 2009;85(2):136-8.
2009: Sparreboom A; Verweij J
Advances in cancer therapeutics.
Clinical pharmacology and therapeutics 2009;85(2):113-7.
2009: Baker S D; Verweij J; Cusatis G A; van Schaik R H; Marsh S; Orwick S J; Franke R M; Hu S; Schuetz E G; Lamba V; Messersmith W A; Wolff A C; Carducci M A; Sparreboom A
Pharmacogenetic pathway analysis of docetaxel elimination.
Clinical pharmacology and therapeutics 2009;85(2):155-63.
2009: Verweij Jaap; Therasse Patrick; Eisenhauer Elizabeth;
Cancer clinical trial outcomes: any progress in tumour-size assessment?
European journal of cancer (Oxford, England : 1990) 2009;45(2):225-7.
2008: Verweij Jaap
'No risk, no fun': challenges for the oncology phase I clinical trial time-performance.
European journal of cancer (Oxford, England : 1990) 2008;44(17):2600-7.
2008: Sciot Raf; Debiec-Rychter Maria; Daugaard Soren; Fisher Cyril; Collin Francoise; van Glabbeke Martine; Verweij Jaap; Blay Jean-Yves; Hogendoorn Pancras C W;
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
European journal of cancer (Oxford, England : 1990) 2008;44(13):1855-60.
2008: de Jong F A; van der Bol J M; Mathijssen R H J; van Gelder T; Wiemer E A C; Sparreboom A; Verweij J
Renal function as a predictor of irinotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2008;84(2):254-62.
2008: Mearadji Amir; den Bakker Michael A; van Geel Albertus N; Eggermont Alexander M M; Sleijfer Stefan; Verweij Jaap; de Wilt Johannes H W; Verhoef Cornelis
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Anti-cancer drugs 2008;19(6):607-12.
2008: Hooker A C; Ten Tije A J; Carducci M A; Weber J; Garrett-Mayer E; Gelderblom H; McGuire W P; Verweij J; Karlsson M O; Baker S D
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
Clinical pharmacology and therapeutics 2008;84(1):111-8.
2008: Filipski Kelly K; Loos Walter J; Verweij Jaap; Sparreboom Alex
Interaction of Cisplatin with the human organic cation transporter 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3875-80.
2008: Ray-Coquard Isabelle; Le Cesne Axel; Whelan Jeremy S; Schoffski Patrick; Bui Binh N; Verweij Jaap; Marreaud Sandrine; van Glabbeke Martine; Hogendoorn Pancras; Blay Jean-Yves
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
The oncologist 2008;13(4):467-73.
2008: Verweij Jaap; Eskens Ferry; de Jonge Maja
The multi-institutional phase I study: disadvantages without advantages?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1915-6.
2008: de Jonge Maja; Verweij Jaap
QTc prolongation and/or oncology drug development: who's in danger?
European journal of cancer (Oxford, England : 1990) 2008;44(4):486-7.
2008: Gardner Erin R; Sparreboom Alex; Verweij Jaap; Figg William D
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer biology & therapy 2008;7(3):412-5.
2008: Sleijfer Stefan; Wiemer Erik; Verweij Jaap
Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Nature clinical practice. Oncology 2008;5(2):102-11.
2008: de Jong Floris A; Sparreboom Alex; Verweij Jaap; Mathijssen Ron H J
Lifestyle habits as a contributor to anti-cancer treatment failure.
European journal of cancer (Oxford, England : 1990) 2008;44(3):374-82.
2008: Eskens F A L M; Mom C H; Planting A S T; Gietema J A; Amelsberg A; Huisman H; van Doorn L; Burger H; Stopfer P; Verweij J; de Vries E G E
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
British journal of cancer 2008;98(1):80-5.
2008: Verweij Jaap; Seynaeve Caroline; Sleijfer Stefan
GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.
Advances in experimental medicine and biology 2008;610():144-54.
2008: Verweij Jaap
Other endpoints in screening studies for soft tissue sarcomas.
The oncologist 2008;13 Suppl 2():27-31.
2008: Hamberg Paul; De Jong Floris A; Brandsma Dieta; Verweij Jaap; Sleijfer Stefan
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Acta oncologica (Stockholm, Sweden) 2008;47(5):974-8.
2007: Engels Frederike K; de Jong Floris A; Mathijssen Ron H J; Erkens Joëlle A; Herings Ron M; Verweij Jaap
Medicinal cannabis in oncology.
European journal of cancer (Oxford, England : 1990) 2007;43(18):2638-44.
2007: Tascilar Metin; Loos Walter J; Seynaeve Caroline; Verweij Jaap; Sleijfer Stefan
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
The oncologist 2007;12(11):1351-60.
2007: Sparreboom Alex; Wolff Antonio C; Mathijssen Ron H J; Chatelut Etienne; Rowinsky Eric K; Verweij Jaap; Baker Sharyn D
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4707-13.
2007: Loos W J; Zamboni W C; Engels F K; de Bruijn P; Lam M H; de Wit R; Verweij J; Wiemer E A C
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
Journal of pharmaceutical and biomedical analysis 2007;45(2):288-94.
2007: de Jong Floris A; van der Bol Jessica M; Mathijssen Ron H J; Loos Walter J; Mathôt Ron A A; Kitzen Jos J E M; van den Bent Martin J; Verweij Jaap
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer biology & therapy 2007;6(9):1368-74.
2007: Sleijfer Stefan; Seynaeve Caroline; Verweij Jaap
Gynaecological sarcomas.
Current opinion in oncology 2007;19(5):492-6.
2007: Engels Frederike K; Loos Walter J; Mathot Ron A A; van Schaik Ron H N; Verweij Jaap
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer chemotherapy and pharmacology 2007;60(4):569-79.
2007: Mathijssen Ron H J; de Jong Floris A; Loos Walter J; van der Bol Jessica M; Verweij Jaap; Sparreboom Alex
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
2007: van der Bol Jessica M; Mathijssen Ron H J; Loos Walter J; Friberg Lena E; van Schaik Ron H N; de Jonge Maja J A; Planting André S Th; Verweij Jaap; Sparreboom Alex; de Jong Floris A
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
2007: Hamberg P; Verweij J; Seynaeve C
Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
European journal of cancer (Oxford, England : 1990) 2007;43(10):1514-28.
2007: Sleijfer Stefan; Wiemer Erik; Seynaeve Caroline; Verweij Jaap
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
The oncologist 2007;12(6):719-26.
2007: Verweij Jaap; Casali Paolo G; Kotasek Dusan; Le Cesne Axel; Reichard Peter; Judson Ian R; Issels R; van Oosterom Allan T; Van Glabbeke Martine; Blay Jean-Yves
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
European journal of cancer (Oxford, England : 1990) 2007;43(6):974-8.
2007: Engels Frederike K; de Jong Floris A; Sparreboom Alex; Mathot Ron A A; Loos Walter J; Kitzen Jos J E M; de Bruijn Peter; Verweij Jaap; Mathijssen Ron H J
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
2007: Scott L; Soepenberg O; Verweij J; de Jonge M J A; Th Planting A S; McGovern D; Principe P; Obach R; Twelves C
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):569-75.
2007: Engels Frederike K; Mathot Ron A A; Verweij Jaap
Alternative drug formulations of docetaxel: a review.
Anti-cancer drugs 2007;18(2):95-103.
2007: Loos Walter J; de Wit Ronald; Freedman Steven J; Van Dyck Kristien; Gambale Jay J; Li Susie; Murphy Gail M; van Noort Connie; de Bruijn Peter; Verweij Jaap
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 2007;59(3):407-12.
2007: Smith N F; Marsh S; Scott-Horton T J; Hamada A; Mielke S; Mross K; Figg W D; Verweij J; McLeod H L; Sparreboom A
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clinical pharmacology and therapeutics 2007;81(1):76-82.
2007: de Jong F A; Scott-Horton T J; Kroetz D L; McLeod H L; Friberg L E; Mathijssen R H; Verweij J; Marsh S; Sparreboom A
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Clinical pharmacology and therapeutics 2007;81(1):42-9.
2007: Leahy Michael; Ray-Coquard Isabelle; Verweij Jaap; Le Cesne Axel; Duffaud Florence; Hogendoorn Pancras C W; Fowst Camilla; de Balincourt Christine; di Paola Eugenio Donato; van Glabbeke Martine; Judson Ian; Blay Jean-Yves;
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2007;43(2):308-15.
2006: Cusatis George; Gregorc Vanesa; Li Jing; Spreafico Anna; Ingersoll Roxann G; Verweij Jaap; Ludovini Vienna; Villa Eugenio; Hidalgo Manuel; Sparreboom Alex; Baker Sharyn D
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Journal of the National Cancer Institute 2006;98(23):1739-42.
2006: Eskens Ferry A L M; Verweij Jaap
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3127-39.
2006: Sleijfer Stefan; Seynaeve Caroline; Wiemer Erik; Verweij Jaap
Practical aspects of managing gastrointestinal stromal tumors.
Clinical colorectal cancer 2006;6 Suppl 1():S18-23.
2006: Felici A; Loos W J; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen R H J; de Jonge M J A
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Cancer chemotherapy and pharmacology 2006;58(5):673-80.
2006: Demetri George D; van Oosterom Allan T; Garrett Christopher R; Blackstein Martin E; Shah Manisha H; Verweij Jaap; McArthur Grant; Judson Ian R; Heinrich Michael C; Morgan Jeffrey A; Desai Jayesh; Fletcher Christopher D; George Suzanne; Bello Carlo L; Huang Xin; Baum Charles M; Casali Paolo G
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 2006;368(9544):1329-38.
2006: Kitzen Jos J E M; Verweij Jaap; Wiemer Erik A C; Loos Walter J
The relevance of microdialysis for clinical on:cology.
Current clinical pharmacology 2006;1(3):255-63.
2006: de Jong Floris A; Kitzen Jos J E M; de Bruijn Peter; Verweij Jaap; Loos Walter J
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer biology & therapy 2006;5(9):1105-10.
2006: de Jong Floris A; Kehrer Diederik F S; Mathijssen Ron H J; Creemers Geert-Jan; de Bruijn Peter; van Schaik Ron H N; Planting André S Th; van der Gaast Ate; Eskens Ferry A L M; Janssen Jos Th P; Ruit Jan B; Verweij Jaap; Sparreboom Alex; de Jonge Maja J A
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
The oncologist 2006;11(8):944-54.
2006: Van Glabbeke Martine; Verweij Jaap; Casali Paolo G; Simes John; Le Cesne Axel; Reichardt Peter; Issels Rolf; Judson Ian R; van Oosterom Allan T; Blay Jean-Yves
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
European journal of cancer (Oxford, England : 1990) 2006;42(14):2277-85.
2006: de Jonge M J A; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt C J A; van Oosterom A;
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2006;42(12):1768-74.
2006: Tascilar Metin; de Jong Floris A; Verweij Jaap; Mathijssen Ron H J
Complementary and alternative medicine during cancer treatment: beyond innocence.
The oncologist 2006;11(7):732-41.
2006: Engels Frederike K; Mathot Ron A A; Loos Walter J; van Schaik Ron H N; Verweij Jaap
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer biology & therapy 2006;5(7):833-9.
2006: de Jonge M J A; Verweij J
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
European journal of cancer (Oxford, England : 1990) 2006;42(10):1351-6.
2006: Lee Chooi P; de Jonge Maja J A; O'Donnell Anne E; Schothorst Kristel L; Hanwell Janet; Chick Jon B; Brooimans Rik A; Adams Laurel M; Drolet Daniel W; de Bono Johann S; Kaye Stan B; Judson Ian R; Verweij Jaap
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2841-8.
2006: Debiec-Rychter Maria; Sciot Raf; Le Cesne Axel; Schlemmer Marcus; Hohenberger Peter; van Oosterom Allan T; Blay Jean-Yves; Leyvraz Serge; Stul Michel; Casali Paolo G; Zalcberg John; Verweij Jaap; Van Glabbeke Martine; Hagemeijer Anne; Judson Ian;
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
European journal of cancer (Oxford, England : 1990) 2006;42(8):1093-103.
2006: Loos Walter J; de Jongh Felix E; Sparreboom Alex; de Wit Ronald; van Boven-van Zomeren Desiree M; Stoter Gerrit; Nooter Kees; Verweij Jaap
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1499-506.
2006: Hoekstra R; de Vos F Y F L; Eskens F A L M; de Vries E G E; Uges D R A; Knight R; Carr R A; Humerickhouse R; Verweij J; Gietema J A
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
European journal of cancer (Oxford, England : 1990) 2006;42(4):467-72.
2006: de Jong Floris A; de Jonge Maja J A; Verweij Jaap; Mathijssen Ron H J
Role of pharmacogenetics in irinotecan therapy.
Cancer letters 2006;234(1):90-106.
2006: de Jonge Maja J A; Verweij Jaap
Renal toxicities of chemotherapy.
Seminars in oncology 2006;33(1):68-73.
2006: Engels Frederike K; Buijs Dirk; Loos Walter J; Verweij Jaap; Bakker Willem H; Krenning Eric P
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.
Anti-cancer drugs 2006;17(1):63-7.
2006: Baker Sharyn D; Sparreboom Alex; Verweij Jaap
Clinical pharmacokinetics of docetaxel : recent developments.
Clinical pharmacokinetics 2006;45(3):235-52.
2005: Sleijfer Stefan; Seynaeve Caroline; Verweij Jaap
Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.
The oncologist 2005;10(10):833-41.
2005: Henningsson Anja; Marsh Sharon; Loos Walter J; Karlsson Mats O; Garsa Adam; Mross Klaus; Mielke Stephan; Viganò Lucia; Locatelli Alberta; Verweij Jaap; Sparreboom Alex; McLeod Howard L
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8097-104.
2005: Verweij Jaap
New targets in oncology drug development.
Clinical advances in hematology & oncology : H&O 2005;3(10):754-5.
2005: Lepper Erin R; Baker Sharyn D; Permenter Matt; Ries Nicole; van Schaik Ron H N; Schenk Paul W; Price Douglas K; Ahn Danielle; Smith Nicola F; Cusatis George; Ingersoll Roxann G; Bates Susan E; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
2005: Hoekstra Ronald; Dumez Herlinde; Eskens Ferry A L M; van der Gaast Ate; Planting Andre S T; de Heus Gerda; Sizer Kurt C; Ravera Christina; Vaidyanathan Sujata; Bucana Corazon; Fidler Isaiah J; van Oosterom Allan T; Verweij Jaap
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6908-15.
2005: Bontenbal Marijke; Creemers Geert-Jan; Braun Hans J; de Boer Auke C; Janssen Jos Th; Leys Rieneke B; Ruit Jan B; Goey Swan Hoo; van der Velden Paul C; Kerkhofs Leon G; Schothorst Kristel L; Schmitz Paul I; Bokma Hansje J; Verweij Jaap; Seynaeve Caroline;
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7081-8.
2005: Verweij Jaap
Pharmaceutical industry, investigators and institutions: Partners or tools?
European journal of cancer (Oxford, England : 1990) 2005;41(15):2204-5.
2005: Van Glabbeke Martine; Verweij Jaap; Casali Paolo G; Le Cesne Axel; Hohenberger Peter; Ray-Coquard Isabelle; Schlemmer Marcus; van Oosterom Allan T; Goldstein David; Sciot Raf; Hogendoorn Pancras C W; Brown Michelle; Bertulli Rossella; Judson Ian R
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5795-804.
2005: Zalcberg John R; Verweij Jaap; Casali Paolo G; Le Cesne Axel; Reichardt Peter; Blay Jean-Yves; Schlemmer Marcus; Van Glabbeke Martine; Brown Michelle; Judson Ian R;
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1751-7.
2005: Hoekstra Ronald; de Vos Filip Y F L; Eskens Ferry A L M; Gietema Jourik A; van der Gaast Ate; Groen Harry J M; Knight Raymond A; Carr Robert A; Humerickhouse Rod A; Verweij Jaap; de Vries Elisabeth G E
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5188-97.
2005: Engels F K; Sparreboom A; Mathot R A A; Verweij J
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
British journal of cancer 2005;93(2):173-7.
2005: Burger Herman; van Tol Hans; Brok Mariël; Wiemer Erik A C; de Bruijn Ernst A; Guetens Gunther; de Boeck Gert; Sparreboom Alex; Verweij Jaap; Nooter Kees
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Cancer biology & therapy 2005;4(7):747-52.
2005: Sparreboom Alex; Loos Walter J; Burger Herman; Sissung Tristan M; Verweij Jaap; Figg William D; Nooter Kees; Gelderblom Hans
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
2005: Engels Frederike K; Verweij Jaap
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
European journal of cancer (Oxford, England : 1990) 2005;41(8):1117-26.
2005: de Jonge Maja J A; van der Gaast Ate; Planting André S T; van Doorn Leny; Lems Aletta; Boot Inge; Wanders Jantien; Satomi Masahiko; Verweij Jaap
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3806-13.
2005: de Jong Floris A; Engels Frederike K; Mathijssen Ron H J; van Zuylen Lia; Verweij Jaap; Peters Remco P H; Sparreboom Alex
Medicinal cannabis in oncology practice: still a bridge too far?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2886-91.
2005: Judson Ian; Ma Peiming; Peng Bin; Verweij Jaap; Racine Amy; di Paola Eugenio Donato; van Glabbeke Martine; Dimitrijevic Sasa; Scurr Michelle; Dumez Herlinde; van Oosterom Allan
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Cancer chemotherapy and pharmacology 2005;55(4):379-86.
2005: Lepper Erin R; Nooter Kees; Verweij Jaap; Acharya Milin R; Figg William D; Sparreboom Alex
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics 2005;6(2):115-38.
2005: Sleijfer Stefan; van der Gaast Ate; Planting André S Th; Stoter Gerrit; Verweij Jaap
The potential of statins as part of anti-cancer treatment.
European journal of cancer (Oxford, England : 1990) 2005;41(4):516-22.
2005: Soepenberg Otto; Dumez Herlinde; Verweij Jaap; de Jong Floris A; de Jonge Maja J A; Thomas José; Eskens Ferry A L M; van Schaik Ron H N; Selleslach Johan; Ter Steeg Judith; Lefebvre Patricia; Assadourian Sylvie; Sanderink Ger-Jan; Sparreboom Alex; van Oosterom Allan T
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
2005: ten Tije Albert J; Verweij Jaap; Carducci Michael A; Graveland Wilfried; Rogers Theresa; Pronk Tatjana; Verbruggen M P; Dawkins Fitzroy; Baker Sharyn D
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1070-7.
2005: Soepenberg Otto; Dumez Herlinde; Verweij Jaap; Semiond Dorothee; deJonge Maja J A; Eskens Ferry A L M; ter Steeg Judith; Selleslach Johan; Assadourian Sylvie; Sanderink Ger-Jan; Sparreboom Alex; van Oosterom A T
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):889-98.
2005: Planting André; van der Gaast Ate; Schöffski Patrick; Bartkowski Michele; Verheij Coleta; Noe Dennis; Ferrante Karen; Verweij Jaap
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(2):136-42.
2005: Planting A; de Jong M; Jansen P; Kerrebijn J; Smith M; Verweij J
Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(1):93-7.
2005: Soepenberg Otto; de Jonge Maja J A; Sparreboom Alex; de Bruin Peter; Eskens Ferry A L M; de Heus Gerda; Wanders Jantien; Cheverton Peter; Ducharme Murray P; Verweij Jaap
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):703-11.
2005: Le Cesne A; Blay J Y; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen O S
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):576-84.
2005: Baker Sharyn D; Li Jing; ten Tije Albert J; Figg William D; Graveland Wilfried; Verweij Jaap; Sparreboom Alex
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clinical pharmacology and therapeutics 2005;77(1):43-53.
2005: Planting A S T; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg M E L; Luyten G P M; de Leeuw K; de Boer-Dennert M; Wissel P S; Jewell R C; Paul E M; Purvis N B; Verweij J
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(1):91-9.
2004: Baker Sharyn D; van Schaik Ron H N; Rivory Laurent P; Ten Tije Albert J; Dinh Kimberly; Graveland Wilfried J; Schenk Paul W; Charles Kellie A; Clarke Stephen J; Carducci Michael A; McGuire William P; Dawkins Fitzroy; Gelderblom Hans; Verweij Jaap; Sparreboom Alex
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8341-50.
2004: Mathijssen Ron H J; de Jong Floris A; van Schaik Ron H N; Lepper Erin R; Friberg Lena E; Rietveld Trinet; de Bruijn Peter; Graveland Wilfried J; Figg William D; Verweij Jaap; Sparreboom Alex
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: de Jonge M J A; Kaye S; Verweij J; Brock C; Reade S; Scurr M; van Doorn L; Verheij C; Loos W; Brindley C; Mistry P; Cooper M; Judson I
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
British journal of cancer 2004;91(8):1459-65.
2004: Verweij Jaap; Casali Paolo G; Zalcberg John; LeCesne Axel; Reichardt Peter; Blay Jean-Yves; Issels Rolf; van Oosterom Allan; Hogendoorn Pancras C W; Van Glabbeke Martine; Bertulli Rossella; Judson Ian
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Lancet 2004;364(9440):1127-34.
2004: de Jong Floris A; Marsh Sharon; Mathijssen Ron H J; King Cristi; Verweij Jaap; Sparreboom Alex; McLeod Howard L
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5889-94.
2004: Paoluzzi Luca; Singh Arun S; Price Douglas K; Danesi Romano; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology 2004;44(8):854-60.
2004: ten Tije Albert J; Loos Walter J; Zhao Ming; Baker Sharyn D; Enting Roelien H; van der Meulen Hans; Verweij Jaap; Sparreboom Alex
Limited cerebrospinal fluid penetration of docetaxel.
Anti-cancer drugs 2004;15(7):715-8.
2004: Acharya Milin R; Baker Sharyn D; Verweij Jaap; Figg William D; Sparreboom Alex
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Analytical biochemistry 2004;331(1):192-4.
2004: Sparreboom Alex; Marsh Sharon; Mathijssen Ron H J; Verweij Jaap; McLeod Howard L
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
Investigational new drugs 2004;22(3):285-9.
2004: Sparreboom Alex; Gelderblom Hans; Marsh Sharon; Ahluwalia Ranjeet; Obach Rosendo; Principe Paola; Twelves Chris; Verweij Jaap; McLeod Howard L
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Clinical pharmacology and therapeutics 2004;76(1):38-44.
2004: Lepper Erin R; Hicks J Kevin; Verweij Jaap; Zhai Suoping; Figg William D; Sparreboom Alex
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):305-10.
2004: de Jong Floris A; Mathijssen Ron H J; Xie Rujia; Verweij Jaap; Sparreboom Alex
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4068-71.
2004: Blay J-Y; Le Cesne A; Verweij J; Scurr M; Seynaeve C; Bonvalot S; Hogendoorn P; Jimeno J; Evrard V; van Glabbeke M; Judson I
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(9):1327-31.
2004: Engels Frederike K; Ten Tije Albert J; Baker Sharyn D; Lee Carlton K K; Loos Walter J; Vulto Arnold G; Verweij Jaap; Sparreboom Alex
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clinical pharmacology and therapeutics 2004;75(5):448-54.
2004: Rudek M A; Sparreboom A; Garrett-Mayer E S; Armstrong D K; Wolff A C; Verweij J; Baker S D
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1170-8.
2004: de Bruijn Peter; Willems Edwin W; Loos Walter J; Verweij Jaap; Sparreboom Alex
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Analytical biochemistry 2004;328(1):84-6.
2004: Mackay Helen J; Hoekstra Ronald; Eskens Ferry A L M; Loos Walker J; Crawford Donna; Voi Maurizio; Van Vreckem Anne; Evans T R Jeffrey; Verweij Jaap
A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(8):2636-44.
2004: Sparreboom A; Kehrer D F S; Mathijssen R H J; Xie R; de Jonge M J A; de Bruijn P; Planting A S T; Eskens F A L M; Verheij C; de Heus G; Klaren A; Zhang S; Verhaeghe T; Palmer P A; Verweij J
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
British journal of cancer 2004;90(8):1508-15.
2004: Baker Sharyn D; Zhao Ming; Lee Carlton K K; Verweij Jaap; Zabelina Yelena; Brahmer Julie R; Wolff Antonio C; Sparreboom Alex; Carducci Michael A
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1976-83.
2004: van Zuylen Lia; Bridgewater John; Sparreboom Alex; Eskens Ferry A L M; de Bruijn Peter; Sklenar Ivo; Planting Andre S T; Choi Les; Bootle Douglas; Mueller Christian; Ledermann Jonathan A; Verweij Jaap
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1949-55.
2004: Polee Marco B; Sparreboom Alex; Eskens Ferry A L M; Hoekstra Ronald; van de Schaaf Jacqueline; Verweij Jaap; Stoter Gerrit; van der Gaast Ate
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1928-34.
2004: Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom A T;
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2004;40(5):689-95.
2004: Soepenberg O; Sparreboom A; de Jonge M J A; Planting A S Th; de Heus G; Loos W J; Hartman C M; Bowden C; Verweij J
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(5):681-8.
2004: ten Tije A J; Smorenburg C H; Seynaeve C; Sparreboom A; Schothorst K L C; Kerkhofs L G M; van Reisen L G P M; Stoter G; Bontenbal M; Verweij J
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
European journal of cancer (Oxford, England : 1990) 2004;40(3):352-7.
2004: Baker Sharyn D; Zhao Ming; He Ping; Carducci Michael A; Verweij Jaap; Sparreboom Alex
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical biochemistry 2004;324(2):276-84.
2004: Soepenberg Otto; de Bruijn Peter; Verweij Jaap; Atsumi Ryo; Sparreboom Alex
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):15-22.
2004: Verweij Jaap
KIT and PDGF as targets.
Cancer treatment and research 2004;120():117-27.
2004: Seynaeve Caroline; Verweij Jaap
Targeted therapy: ready for prime time?
Cancer treatment and research 2004;120():1-15.
2003: de Jong Floris A; Verweij Jaap
Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
Expert review of anticancer therapy 2003;3(6):757-66.
2003: Ten Tije Albert J; Loos Walter J; Verweij Jaap; Baker Sharyn D; Dinh Kimberly; Figg William D; Sparreboom Alex
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
2003: Loos Walter J; Baker Sharyn D; Verweij Jaap; Boonstra Joke G; Sparreboom Alex
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clinical pharmacology and therapeutics 2003;74(4):364-71.
2003: de Jong Floris A; Mathijssen Ron H J; de Bruijn Peter; Loos Walter J; Verweij Jaap; Sparreboom Alex
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.
2003: Gelderblom Hans; Salazar Ramon; Verweij Jaap; Pentheroudakis George; de Jonge Maja J A; Devlin Martin; van Hooije Christel; Seguy Francis; Obach Rosendo; Pruñonosa Joan; Principe Paola; Twelves Chris
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4101-7.
2003: Verweij J; van Oosterom A; Blay J-Y; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn P C W; di Paola E D; Brown M; Nielsen O S
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
European journal of cancer (Oxford, England : 1990) 2003;39(14):2006-11.
2003: ten Tije Albert J; Synold Timothy W; Spicer Darcy; Verweij Jaap; Doroshow James H; Sparreboom Alex
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Investigational new drugs 2003;21(3):291-8.
2003: Mathijssen Ron H J; Marsh Sharon; Karlsson Mats O; Xie Rujia; Baker Sharyn D; Verweij Jaap; Sparreboom Alex; McLeod Howard L
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3246-53.
2003: Ten Tije Albert J; Verweij Jaap; Sparreboom Alex; Van Der Gaast Ate; Fowst Camilla; Fiorentini Francesco; Tursi Jennifer; Antonellini Alessandro; Mantel Marijke; Hartman Carla M; Stoter Gerrit; Planting Andre S T; De Jonge Maja J A
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2957-64.
2003: Gelderblom H; Loos W J; Sparreboom A; Soepenberg O; de Jonge M J A; van Boven-van Zomeren D M; Verweij J
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1542-6.
2003: Gelderblom Hans; Baker Sharyn D; Zhao Ming; Verweij Jaap; Sparreboom Alex
Distribution of paclitaxel in plasma and cerebrospinal fluid.
Anti-cancer drugs 2003;14(5):365-8.
2003: Hoekstra Ronald; Verweij Jaap; Eskens Ferry A L M
Clinical trial design for target specific anticancer agents.
Investigational new drugs 2003;21(2):243-50.
2003: Eskens F A L M; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom A T
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(7):917-26.
2003: de Jongh F E; van Veen R N; Veltman S J; de Wit R; van der Burg M E L; van den Bent M J; Planting A S Th; Graveland W J; Stoter G; Verweij J
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.
British journal of cancer 2003;88(8):1199-206.
2003: Burger H; den Bakker M A; Stoter G; Verweij J; Nooter K
Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.
European journal of cancer (Oxford, England : 1990) 2003;39(6):793-9.
2003: Schellens J H M; Planting A S T; van Zandwijk N; Ma J; Maliepaard M; van der Burg M E L; de Boer-Dennert M; Brouwer E; van der Gaast A; van den Bent M J; Verweij J
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
British journal of cancer 2003;88(6):814-21.
2003: Loos Walter J; Gelderblom Hans; Verweij Jaap; van Boven-van Zomeren Desirée M; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Anti-cancer drugs 2003;14(3):227-32.
2003: Sausville Edward; Verweij Jaap
Highlights from the EORTC-NCI-AACR 2002 meeting: molecular targets and cancer therapeutics.
Clinical advances in hematology & oncology : H&O 2003;1(1):22-3.
2003: Sparreboom Alex; Wolff Antonio C; Verweij Jaap; Zabelina Yelena; van Zomeren Desiree M; McIntire Gregory L; Swindell Charles S; Donehower Ross C; Baker Sharyn D
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):151-9.
2003: Smorenburg Carolien H; Sparreboom Alex; Bontenbal Marijke; Stoter Gerrit; Nooter Kees; Verweij Jaap
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):197-202.
2003: Smorenburg C H; ten Tije A J; Verweij J; Bontenbal M; Mross K; van Zomeren D M; Seynaeve C; Sparreboom A
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(2):196-202.
2003: van der Hul René L; Seynaeve Caroline; van Geel Bert N; Verweij Jaap
Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity.
Sarcoma 2003;7(3-4):153-7.
2003: Soepenberg Otto; Sparreboom Alex; Verweij Jaap
Clinical studies of camptothecin and derivatives.
The Alkaloids. Chemistry and biology 2003;60():1-50.
2003: ten Tije Albert J; Verweij Jaap; Loos Walter J; Sparreboom Alex
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clinical pharmacokinetics 2003;42(7):665-85.
2002: de Jonge M J A; Verweij J; van der Gaast A; Valota O; Mora O; Planting A S Th; Mantel M A; Bosch S Van Den; Lechuga M J; Fiorentini F; Hess D; Sessa C
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(18):2407-15.
2002: de Jongh F E; de Wit R; Verweij J; Sparreboom A; van den Bent M J; Stoter G; van der Burg M E L
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(15):2005-13.
2002: van Oosterom Allan T; Judson Ian R; Verweij Jaap; Stroobants Sigrid; Dumez Herlinde; Donato di Paola Eugenio; Sciot Raf; Van Glabbeke Martine; Dimitrijevic Sasa; Nielsen Ole S;
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 5():S83-7.
2002: Xie Rujia; Mathijssen Ron H J; Sparreboom Alex; Verweij Jaap; Karlsson Mats O
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Clinical pharmacology and therapeutics 2002;72(3):265-75.
2002: Felici A; Verweij J; Sparreboom A
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
European journal of cancer (Oxford, England : 1990) 2002;38(13):1677-84.
2002: Mathijssen Ron H J; Verweij Jaap; de Bruijn Peter; Loos Walter J; Sparreboom Alex
Effects of St. John's wort on irinotecan metabolism.
Journal of the National Cancer Institute 2002;94(16):1247-9.
2002: Loos Walter J; Szebeni Janos; ten Tije Albert J; Verweij Jaap; van Zomeren Desirée M; Chung Kyu-nung; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Anti-cancer drugs 2002;13(7):767-75.
2002: Xie Rujia; Mathijssen Ron H J; Sparreboom Alex; Verweij Jaap; Karlsson Mats O
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3293-301.
2002: de Jonge Maja J A; Glimelius B; Verweij Jaap; Van Groeningen C; Bonneterre J; de Vries E G E; Culine S; Young J; Smith Rob; Droz J
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Anti-cancer drugs 2002;13(6):645-53.
2002: Dumez H; Louwerens M; Pawinsky A; Planting A S Th; de Jonge M J A; Van Oosterom A T; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Anti-cancer drugs 2002;13(6):583-93.
2002: Kehrer Diederik F S; Mathijssen Ron H J; Verweij Jaap; de Bruijn Peter; Sparreboom Alex
Modulation of irinotecan metabolism by ketoconazole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3122-9.
2002: Polee M B; Verweij J; Siersema P D; Tilanus H W; Splinter T A W; Stoter G; Van der Gaast A
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1495-500.
2002: Mathijssen R H J; Verweij J; Loos W J; de Bruijn P; Nooter K; Sparreboom A
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
British journal of cancer 2002;87(2):144-50.
2002: Mathijssen Ron H J; Loos Walter J; Verweij Jaap; Sparreboom Alex
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Current cancer drug targets 2002;2(2):103-23.
2002: van Zuylen L; Sparreboom A; van der Gaast A; Nooter K; Eskens F A L M; Brouwer E; Bol C J; de Vries R; Palmer P A; Verweij J
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1090-9.
2002: Gelderblom Hans; Verweij Jaap; van Zomeren Desirée M; Buijs Dirk; Ouwens Linda; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1237-41.
2002: de Jonge Maja J A; Punt Cornelis J A; Sparreboom Alex; Planting André S T; Peters M E W J; van De Schraaf Jacqueline; Jackman Ann; Smith Rob; de Mulder Pieter H M; Verweij Jaap
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1923-31.
2002: Loos Walter J; Verweij Jaap; Kehrer Diederik F S; de Bruijn Peter; de Groot Franciscus M H; Hamilton Marta; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):856-62.
2002: Polee M B; Eskens F A L M; van der Burg M E L; Splinter T A W; Siersema P D; Tilanus H W; Verweij J; Stoter G; van der Gaast A
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
British journal of cancer 2002;86(5):669-73.
2002: Svancárová L; Blay J Y; Judson I R; van Hoesel Q G C M; van Oosterom A T; le Cesne A; Keizer H J; Hermans C; van Glabbeke M; Verweij J; Hogendoorn P C W; Nielsen O S
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38(4):556-9.
2002: Louwerens M; Smorenburg C; Sparreboom A; Loos W J; Verweij J; de Wit R
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(4):497-504.
2002: Kehrer Diederik F S; Bos Annelies M; Verweij Jaap; Groen Harry J; Loos Walter J; Sparreboom Alex; de Jonge Maja J A; Hamilton Marta; Cameron Terri; de Vries Elisabeth G E
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1222-31.
2002: Schellens J H M; Heinrich B; Lehnert M; Gore M E; Kaye S B; Dombernowsky P; Paridaens R; van Oosterom A T; Verweij J; Loos W J; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel P S; Gamucci T; Hanauske A R
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
2002: van der Burg M E L; de Wit R; van Putten W L J; Logmans A; Kruit W H J; Stoter G; Verweij J
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
British journal of cancer 2002;86(1):19-25.
2002: Loos Walter J; van Zomeren Desirée M; Gelderblom Hans; Verweij Jaap; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(1):99-105.
2002: Gelderblom Hans; Mross Klaus; ten Tije Albert J; Behringer Dirk; Mielke Stephan; van Zomeren Desirée M; Verweij Jaap; Sparreboom Alex
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):574-81.
2002: Mathijssen Ron H J; Verweij Jaap; de Jonge Maja J A; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):81-7.
2002: Gelderblom H; Loos W J; Verweij J; van der Burg M E L; de Jonge M J A; Brouwer E; Nooter K; Stoter G; Sparreboom A
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):205-13.
2002: Sparreboom A; de Jonge M J A; Verweij J
The use of oral cytotoxic and cytostatic drugs in cancer treatment.
European journal of cancer (Oxford, England : 1990) 2002;38(1):18-22.
2002: Verweij Jaap
Sarcomas.
Cancer chemotherapy and biological response modifiers 2002;20():559-73.
2001: Smorenburg C H; Sparreboom A; Bontenbal M; Verweij J
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2310-23.
2001: Gelderblom H; Sparreboom A; de Jonge M J; Loos W J; Wilms E; Mantel M A; Hennis B; Camlett I; Verweij J; van der Burg M E
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
British journal of cancer 2001;85(8):1124-9.
2001: van Oosterom A T; Judson I; Verweij J; Stroobants S; Donato di Paola E; Dimitrijevic S; Martens M; Webb A; Sciot R; Van Glabbeke M; Silberman S; Nielsen O S;
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet 2001;358(9291):1421-3.
2001: Henningsson A; Karlsson M O; Viganò L; Gianni L; Verweij J; Sparreboom A
Mechanism-based pharmacokinetic model for paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4065-73.
2001: Verweij J; Judson I; van Oosterom A
STI571: a magic bullet?
European journal of cancer (Oxford, England : 1990) 2001;37(15):1816-9.
2001: Schellens J H; Planting A S; Ma J; Maliepaard M; de Vos A; de Boer Dennert M; Verweij J
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
Anti-cancer drugs 2001;12(8):667-75.
2001: de Jongh F E; Verweij J; Loos W J; de Wit R; de Jonge M J; Planting A S; Nooter K; Stoter G; Sparreboom A
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3733-9.
2001: Gelderblom H; Verweij J; Nooter K; Sparreboom A
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1590-8.
2001: Mathijssen R H; van Alphen R J; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2182-94.
2001: Schellens J H; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox E H; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos W J; Verweij J; Pavlidis N; Hanauske A R;
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Anti-cancer drugs 2001;12(7):583-90.
2001: Levitt N C; Eskens F A; O'Byrne K J; Propper D J; Denis L J; Owen S J; Choi L; Foekens J A; Wilner S; Wood J M; Nakajima M; Talbot D C; Steward W P; Harris A L; Verweij J
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1912-22.
2001: Yamamoto W; Verweij J; de Bruijn P; de Jonge M J; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Anti-cancer drugs 2001;12(5):419-32.
2001: Gortzak E; Azzarelli A; Buesa J; Bramwell V H; van Coevorden F; van Geel A N; Ezzat A; Santoro A; Oosterhuis J W; van Glabbeke M; Kirkpatrick A; Verweij J;
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1096-103.
2001: van Zuylen L; Verweij J; Sparreboom A
Role of formulation vehicles in taxane pharmacology.
Investigational new drugs 2001;19(2):125-41.
2001: Kehrer D F; Sparreboom A; Verweij J; de Bruijn P; Nierop C A; van de Schraaf J; Ruijgrok E J; de Jonge M J
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1136-41.
2001: Judson I; Radford J A; Harris M; Blay J Y; van Hoesel Q; le Cesne A; van Oosterom A T; Clemons M J; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2001;37(7):870-7.
2001: van Zuylen L; Karlsson M O; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
Cancer chemotherapy and pharmacology 2001;47(4):309-18.
2001: de Bruijn P; Kehrer D F; Verweij J; Sparreboom A
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism.
Journal of chromatography. B, Biomedical sciences and applications 2001;753(2):395-400.
2001: Smorenburg C H; Bontenbal M; Seynaeve C; van Zuylen C; de Heus G; Verweij J; de Wit R
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.
Breast cancer research and treatment 2001;66(1):83-7.
2001: Kehrer D F; Soepenberg O; Loos W J; Verweij J; Sparreboom A
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anti-cancer drugs 2001;12(2):89-105.
2001: Eskens F A; Awada A; Cutler D L; de Jonge M J; Luyten G P; Faber M N; Statkevich P; Sparreboom A; Verweij J; Hanauske A R; Piccart M;
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1167-75.
2001: Smorenburg C H; Bontenbal M; Verweij J
Capecitabine in breast cancer: current status.
Clinical breast cancer 2001;1(4):288-93; discussion 294.
2001: Verweij J
Sarcomas.
Cancer chemotherapy and biological response modifiers 2001;19():639-51.
2001: Hoekstra R; Eskens F A; Verweij J
Matrix metalloproteinase inhibitors: current developments and future perspectives.
The oncologist 2001;6(5):415-27.
2000: Smorenburg C H; Seynaeve C; Bontenbal M; Planting A S; Sindermann H; Verweij J
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Anti-cancer drugs 2000;11(10):825-8.
2000: Loos W J; Gelderblom H J; Verweij J; Brouwer E; de Jonge M J; Sparreboom A
Gender-dependent pharmacokinetics of topotecan in adult patients.
Anti-cancer drugs 2000;11(9):673-80.
2000: Eskens F A; Stoter G; Verweij J
Farnesyl transferase inhibitors: current developments and future perspectives.
Cancer treatment reviews 2000;26(5):319-32.
2000: Brouwer E; Verweij J; De Bruijn P; Loos W J; Pillay M; Buijs D; Sparreboom A
Measurement of fraction unbound paclitaxel in human plasma.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1141-5.
2000: Gelderblom A J; Loos W J; de Jonge M J; Sparreboom A; Planting A S; van der Burg M E; Brouwer E; Verheij C; Ouwens L; Hearn S; Verweij J
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1205-7.
2000: Kehrer D F; Yamamoto W; Verweij J; de Jonge M J; de Bruijn P; Sparreboom A
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3451-8.
2000: van Zuylen L; Nooter K; Sparreboom A; Verweij J
Development of multidrug-resistance convertors: sense or nonsense?
Investigational new drugs 2000;18(3):205-20.
2000: Schrijvers D; Pronk L; Highley M; Bruno R; Locci-Tonelli D; De Bruijn E; Van Oosterom A T; Verweij J
Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.
American journal of clinical oncology 2000;23(4):358-63.
2000: Verweij J; de Jonge M J
Achievements and future of chemotherapy.
European journal of cancer (Oxford, England : 1990) 2000;36(12):1479-87.
2000: Gwyther S J; Nielsen O S; Judson I R; van Glabbeke M; Verweij J
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
Anti-cancer drugs 2000;11(6):433-7.
2000: Gamucci T; Paridaens R; Heinrich B; Schellens J H; Pavlidis N; Verweij J; Sessa C; Kaye S; Roelvink M; Wanders J; Hanauske A
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):793-7.
2000: Loos W J; Gelderblom H; Sparreboom A; Verweij J; de Jonge M J
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2685-9.
2000: van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2598-603.
2000: Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer H J; Van Hoesel Q; Blay J Y; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2676-84.
2000: Pronk L C; Vasey P; Sparreboom A; Reigner B; Planting A S; Gordon R J; Osterwalder B; Verweij J; Twelves C
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
British journal of cancer 2000;83(1):22-9.
2000: van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos W J; Sparreboom A
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Anti-cancer drugs 2000;11(5):331-7.
2000: Loos W J; de Bruijn P; Verweij J; Sparreboom A
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs 2000;11(5):315-24.
2000: Eskens F A; Greim G A; van Zuylen C; Wolff I; Denis L J; Planting A S; Muskiet F A; Wanders J; Barbet N C; Choi L; Capdeville R; Verweij J; Hanauske A R; Bruntsch U
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1736-43.
2000: de Jonge M J; Loos W J; Gelderblom H; Planting A S; van der Burg M E; Sparreboom A; Brouwer E; van Beurden V; Mantel M A; Doyle E; Hearn S; Ross G; Verweij J
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2104-15.
2000: Verweij J; Lee S M; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola E D; van Glabbeke M; Tonelli D; Judson I R
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2081-6.
2000: Kruijtzer CMF; Verweij J; Schellens J H; Beijnen J H; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink W W
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: van Zuylen L; Sparreboom A; van der Gaast A; van der Burg M E; van Beurden V; Bol C J; Woestenborghs R; Palmer P A; Verweij J
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1365-71.
2000: Gelderblom H; Loos W J; Verweij J; de Jonge M J; Sparreboom A
Topotecan lacks third space sequestration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1288-92.
2000: Van Cutsem E; Findlay M; Osterwalder B; Kocha W; Dalley D; Pazdur R; Cassidy J; Dirix L; Twelves C; Allman D; Seitz J F; Schölmerich J; Burger H U; Verweij J
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1337-45.
2000: Zhou H; Choi L; Lau H; Bruntsch U; Vries E E; Eckhardt G; Oosterom A T; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Journal of clinical pharmacology 2000;40(3):275-83.
2000: Eskens F A; Levitt N C; Sparreboom A; Choi L; Mather R; Verweij J; Harris A L
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):431-3.
2000: Loos W J; Kehrer D; Brouwer E; Verweij J; de Bruijn P; Hamilton M; Gill S; Nooter K; Stoter G; Sparreboom A
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(1):155-63.
2000: Nielsen O S; Judson I; van Hoesel Q; le Cesne A; Keizer H J; Blay J Y; van Oosterom A; Radford J A; Svancárová L; Krzemienlecki K; Hermans C; van Glabbeke M; Oosterhuis J W; Verweij J
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2000;36(1):61-7.
2000: de Jonge M J; Verweij J; de Bruijn P; Brouwer E; Mathijssen R H; van Alphen R J; de Boer-Dennert M M; Vernillet L; Jacques C; Sparreboom A
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):195-203.
2000: de Jonge M J; Sparreboom A; Planting A S; van der Burg M E; de Boer-Dennert M M; ter Steeg J; Jacques C; Verweij J
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):187-94.
1999: Loos W J; de Bruijn P; van Zuylen L; Verweij J; Nooter K; Stoter G; Sparreboom A
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):293-7.
1999: Sparreboom A; Loos W J; Nooter K; Stoter G; Verweij J
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(1):111-9.
1999: Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(11):1300-5.
1999: Planting A S; Schellens J H; van der Burg M E; de Boer-Dennert M; Winograd B; Stoter G; Verweij J
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Anti-cancer drugs 1999;10(9):821-7.
1999: van Tellingen O; Beijnen J H; Verweij J; Scherrenburg E J; Nooijen W J; Sparreboom A
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Verweij J; Seynaeve C
The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting.
Seminars in radiation oncology 1999;9(4):352-9.
1999: Sparreboom A; Planting A S; Jewell R C; van der Burg M E; van der Gaast A; de Bruijn P; Loos W J; Nooter K; Chandler L H; Paul E M; Wissel P S; Verweij J
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Anti-cancer drugs 1999;10(8):719-28.
1999: Loos W J; Verweij J; Gelderblom H J; de Jonge M J; Brouwer E; Dallaire B K; Sparreboom A
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.
Anti-cancer drugs 1999;10(8):705-10.
1999: de Jonge M J; Verweij J; Planting A S; van der Burg M E; Stoter G; de Boer-Dennert M M; de Bruijn P; Brouwer E; Vernillet L; Sparreboom A
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2012-7.
1999: de Jonge M J; Punt C J; Gelderblom A H; Loos W J; van Beurden V; Planting A S; van der Burg M E; van Maanen L W; Dallaire B K; Verweij J; Wagener D J; Sparreboom A
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2219-26.
1999: Verweij J
Rational design of new tumoractivated cytotoxic agents.
Oncology 1999;57 Suppl 1():9-15.
1999: de Wit R; van der Zee J; van der Burg M E; Kruit W H; Logmans A; van Rhoon G C; Verweij J
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix.
British journal of cancer 1999;80(9):1387-91.
1999: Sparreboom A; de Jonge M J; Punt C J; Loos W J; Nooter K; Stoter G; Porro M G; Verweij J
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):816-20.
1999: Planting A S; Catimel G; de Mulder P H; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken J B
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):693-700.
1999: de Jonge M J; Verweij J; Loos W J; Dallaire B K; Sparreboom A
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacology and therapeutics 1999;65(5):491-9.
1999: van Zuylen L; Schellens J H; Goey S H; Pronk L C; de Boer-Dennert M M; Loos W J; Ma J; Stoter G; Verweij J
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
1999: Sparreboom A; van Zuylen L; Brouwer E; Loos W J; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Cancer research 1999;59(7):1454-7.
1999: Awada A; Punt C J; Piccart M J; Van Tellingen O; Van Manen L; Kerger J; Groot Y; Wanders J; Verweij J; Wagener D J
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
British journal of cancer 1999;79(9-10):1454-61.
1999: Seynaeve C; Verweij J
High-dose chemotherapy in adult sarcomas: no standard yet.
Seminars in oncology 1999;26(1):119-33.
1999: Mathijssen R H; van Alphen R J; de Jonge M J; Verweij J; de Bruijn P; Loos W J; Nooter K; Vernillet L; Stoter G; Sparreboom A
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Anti-cancer drugs 1999;10(1):9-16.
1999: Schöffski P; Catimel G; Planting A S; Droz J P; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske A R
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):119-22.
1999: Gerrits C J; Schellens J H; Burris H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Von Hoff D D; Verweij J
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1999: de Bruijn P; Verweij J; Loos W J; Kolker H J; Planting A S; Nooter K; Stoter G; Sparreboom A
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
Analytical biochemistry 1999;266(2):216-21.
1999: Verweij J; Sparreboom A; Nooter K
Mitomycins.
Cancer chemotherapy and biological response modifiers 1999;18():46-58.
1999: Gelderblom H A; DE Jonge M J; Sparreboom A; Verweij J
Oral topoisomerase 1 inhibitors in adult patients: present and future.
Investigational new drugs 1999;17(4):401-15.
1999: Pronk L C; van Putten W L; van Beurden V; de Boer-Dennert M; Stoter G; Verweij J
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Cancer chemotherapy and pharmacology 1999;43(2):173-7.
1998: Nielsen O S; Dombernowsky P; Mouridsen H; Crowther D; Verweij J; Buesa J; Steward W; Daugaard S; van Glabbeke M; Kirkpatrick A; Tursz T
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
British journal of cancer 1998;78(12):1634-9.
1998: Sparreboom A; de Jonge M J; de Bruijn P; Brouwer E; Nooter K; Loos W J; van Alphen R J; Mathijssen R H; Stoter G; Verweij J
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2747-54.
1998: Pronk L C; Hilkens P H; van den Bent M J; van Putten W L; Stoter G; Verweij J
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Anti-cancer drugs 1998;9(9):759-64.
1998: van den Bent M J; Schellens J H; Vecht C J; Sillevis Smit P A; Loosveld O J; Ma J; Tijssen C C; Jansen R L; Kros J M; Verweij J
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.
European journal of cancer (Oxford, England : 1990) 1998;34(10):1570-4.
1998: Mackean M; Planting A; Twelves C; Schellens J; Allman D; Osterwalder B; Reigner B; Griffin T; Kaye S; Verweij J
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2977-85.
1998: Sparreboom A; Verweij J; van der Burg M E; Loos W J; Brouwer E; Viganò L; Locatelli A; de Vos A I; Nooter K; Stoter G; Gianni L
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1937-42.
1998: Sparreboom A; de Jonge M J; Punt C J; Nooter K; Loos W J; Porro M G; Verweij J
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1915-9.
1998: Brouwer E; Verweij J; Hauns B; Loos W J; Nooter K; Mross K; Stoter G; Sparreboom A
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Analytical biochemistry 1998;261(2):198-202.
1998: Sparreboom A; de Bruijn P; de Jonge M J; Loos W J; Stoter G; Verweij J; Nooter K
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):225-35.
1998: Gerrits C J; Burris H; Schellens J H; Planting A S; van den Burg M E; Rodriguez G I; van Beurden V; Loos W J; Hudson I; Fields S; Verweij J; von Hoff D D
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: de Jonge M J; Sparreboom A; Verweij J
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Cancer treatment reviews 1998;24(3):205-20.
1998: de Wit R; Kruit W H; Lamers C H; van 't Veer M B; Luyten A A; van Beurden V; Harteveld M; Planting A S; Schmitz P I; Stoter G; Bolhuis R L; Verweij J
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
British journal of cancer 1998;77(12):2363-6.
1998: de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
British journal of cancer 1998;77(9):1487-91.
1998: Ma J; Maliepaard M; Nooter K; Loos W J; Kolker H J; Verweij J; Stoter G; Schellens J H
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
British journal of cancer 1998;77(10):1645-52.
1998: Gerrits C J; Burris H; Schellens J H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Fields S; Von Hoff D D; Verweij J
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):941-8.
1998: Pronk L C; Schrijvers D; Schellens J H; de Bruijn E A; Planting A S; Locci-Tonelli D; Groult V; Verweij J; van Oosterom A T
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Seminars in oncology 1998;25(1 Suppl 2):23-8.
1998: van den Bent M J; Hilkens P H; Sillevis Smitt P A; van Raaij-van den Aarssen V J; Bontenbal M; Verweij J
Lhermitte's sign following chemotherapy with docetaxel.
Neurology 1998;50(2):563-4.
1998: Sparreboom A; de Bruijn P; Nooter K; Loos W J; Stoter G; Verweij J
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):159-64.
1998: Sparreboom A; Loos W J; Verweij J; de Vos A I; van der Burg M E; Stoter G; Nooter K
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Analytical biochemistry 1998;255(2):171-5.
1998: Ma J; Maliepaard M; Nooter K; Boersma A W; Verweij J; Stoter G; Schellens J H
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Cancer chemotherapy and pharmacology 1998;41(4):307-16.
1998: Pronk L C; Schrijvers D; Schellens J H; de Bruijn E A; Planting A S; Locci-Tonelli D; Groult V; Verweij J; van Oosterom A T
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
British journal of cancer 1998;77(1):153-8.
1998: Ma J; Maliepaard M; Kolker H J; Verweij J; Schellens J H
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Cancer chemotherapy and pharmacology 1998;41(3):186-92.
1997: de Vos A I; Nooter K; Verweij J; Loos W J; Brouwer E; de Bruijn P; Ruijgrok E J; van der Burg M E; Stoter G; Sparreboom A
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1145-50.
1997: de Bruijn P; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):277-85.
1997: Loos W J; Sparreboom A; Verweij J; Nooter K; Stoter G; Schellens J H
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
1997: Goey S H; Verweij J; Bolhuis R L; de Gooyer D; Eggermont A M; Schmitz P I; Stoter G
Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients.
Cancer immunology, immunotherapy : CII 1997;44(5):301-4.
1997: Verweij J; Nielsen O S; Therasse P; van Oosterom A T
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1045-9.
1997: Loos W J; Verweij J; Nooter K; Stoter G; Sparreboom A
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(2):437-41.
1997: van den Bent M J; van Raaij-van den Aarssen V J; Verweij J; Doorn P A; Sillevis Smitt P A
Progression of paclitaxel-induced neuropathy following discontinuation of treatment.
Muscle & nerve 1997;20(6):750-2.
1997: Gwyther S; Bolis G; Gore M; ten Bokkel Huinink W; Verweij J; Hudson I R; Despax R; Jiménez-Lacave A
Experience with independent radiological review during a topotecan trial in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(5):463-8.
1997: Creemers G J; Gerrits C J; Eckardt J R; Schellens J H; Burris H A; Planting A S; Rodriguez G I; Loos W J; Hudson I; Broom C; Verweij J; Von Hoff D D
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: Pronk L C; Schellens J H; Planting A S; van den Bent M J; Hilkens P H; van der Burg M E; de Boer-Dennert M; Ma J; Blanc C; Harteveld M; Bruno R; Stoter G; Verweij J
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1071-9.
1997: Hilkens P H; Verweij J; Vecht C J; Stoter G; van den Bent M J
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):187-90.
1997: Planting A S; de Mulder P H; de Graeff A; Verweij J
Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
European journal of cancer (Oxford, England : 1990) 1997;33(1):61-5.
1997: Verweij J
Mitomycins.
Cancer chemotherapy and biological response modifiers 1997;17():46-58.
1997: Schellens J H; Van de Vrie W; Loos W J; Kolker H J; Verweij J; Stoter G; Durante N M; Eggermont A M
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
Cancer chemotherapy and pharmacology 1997;41(1):48-52.
1997: Denis L J; Verweij J
Matrix metalloproteinase inhibitors: present achievements and future prospects.
Investigational new drugs 1997;15(3):175-85.
1997: de Boer-Dennert M; de Wit R; Schmitz P I; Djontono J; v Beurden V; Stoter G; Verweij J
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.
British journal of cancer 1997;76(8):1055-61.
1997: Gerrits C J; de Jonge M J; Schellens J H; Stoter G; Verweij J
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
British journal of cancer 1997;76(7):952-62.
1997: Gerrits C J; Schellens J H; Creemers G J; Wissel P; Planting A S; Pritchard J F; DePee S; de Boer-Dennert M; Harteveld M; Verweij J
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
British journal of cancer 1997;76(7):946-51.
1997: Verweij J; Pinedo H M
Adjuvant chemotherapy of soft tissue sarcomas.
Cancer treatment and research 1997;91():173-87.
1997: Aamdal S; Bruntsch U; Kerger J; Verweij J; ten Bokkel Huinink W; Wanders J; Rastogi R; Franklin H R; Kaye S B
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity.
Cancer chemotherapy and pharmacology 1997;40(5):439-43.
1997: Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(4):347-52.
1997: Hilkens P H; Pronk L C; Verweij J; Vecht C J; van Putten W L; van den Bent M J
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
British journal of cancer 1997;75(3):417-22.
1996: Planting A S; de Wit R; van der Burg M E; Stoter G; Verweij J
Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(10):1080-2.
1996: Goey S H; Gratama J W; Primrose J N; Ward U; Mertelsmann R H; Osterwalder B; Verweij J; Stoter G
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
British journal of cancer 1996;74(12):2018-23.
1996: McLeod H L; Murray L S; Wanders J; Setanoians A; Graham M A; Pavlidis N; Heinrich B; ten Bokkel Huinink W W; Wagener D J; Aamdal S; Verweij J
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
British journal of cancer 1996;74(12):1944-8.
1996: Creemers G J; Bolis G; Gore M; Scarfone G; Lacave A J; Guastalla J P; Despax R; Favalli G; Kreinberg R; Van Belle S; Hudson I; Verweij J; Ten Bokkel Huinink W W
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3056-61.
1996: Goey S H; Verweij J; Stoter G
Immunotherapy of metastatic renal cell cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):887-900.
1996: Planting A S; van der Burg M E; Goey S H; Schellens J H; Vecht C; de Boer-Dennert M; Stoter G; Verweij J
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2026-8.
1996: Dirix L Y; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink W W; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2019-22.
1996: Verweij J; de Mulder P H; de Graeff A; Vermorken J B; Wildiers J; Kerger J; Schornagel J; Cognetti F; Kirkpatrick A; Sahmoud T; Lefebvre J L
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):867-9.
1996: de Wit R; Verweij J; Bontenbal M; Kruit W H; Seynaeve C; Schmitz P I; Stoter G
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
Journal of the National Cancer Institute 1996;88(19):1393-8.
1996: Creemers G J; Gerrits C J; Schellens J H; Planting A S; van der Burg M E; van Beurden V M; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
1996: Pavlidis N; Hanauske A R; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):529-31.
1996: de Wit R; Beijnen J H; van Tellingen O; Schellens J H; de Boer-Dennert M; Verweij J
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: Verweij J; de Wit R; de Mulder P H
Optimal control of acute cisplatin-induced emesis.
Oncology 1996;53 Suppl 1():56-64.
1996: Schellens J H; Ma J; Planting A S; van der Burg M E; van Meerten E; de Boer-Dennert M; Schmitz P I; Stoter G; Verweij J
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
British journal of cancer 1996;73(12):1569-75.
1996: Schellens J H; Creemers G J; Beijnen J H; Rosing H; de Boer-Dennert M; McDonald M; Davies B; Verweij J
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: Loos W J; Stoter G; Verweij J; Schellens J H
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Journal of chromatography. B, Biomedical applications 1996;678(2):309-15.
1996: Gerrits C J; Creemers G J; Schellens J H; Wissel P; Planting A S; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
British journal of cancer 1996;73(6):744-50.
1996: de Wit R; Schmitz P I; Verweij J; de Boer-Dennert M; de Mulder P H; Planting A S; van der Burg M E; Stoter G
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):644-51.
1996: Kaplan S; Hanauske A R; Pavlidis N; Bruntsch U; te Velde A; Wanders J; Heinrich B; Verweij J
Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
British journal of cancer 1996;73(3):403-5.
1996: Verweij J; Wanders J; Gil T; Schöffski P; Catimel G; te Velde A; de Mulder P H
Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
British journal of cancer 1996;73(3):400-2.
1996: Hanauske A R; Catimel G; Aamdal S; ten Bokkel Huinink W; Paridaens R; Pavlidis N; Kaye S B; te Velde A; Wanders J; Verweij J
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
British journal of cancer 1996;73(3):397-9.
1996: Schellens J H; Pronk L C; Verweij J
Emerging drug treatments for solid tumours.
Drugs 1996;51(1):45-72.
1996: Hilkens P H; Verweij J; Stoter G; Vecht C J; van Putten W L; van den Bent M J
Peripheral neurotoxicity induced by docetaxel.
Neurology 1996;46(1):104-8.
1996: Verweij J
New promising anticancer agents in development: what comes next?
Cancer chemotherapy and pharmacology 1996;38 Suppl():S3-10.
1996: Ma J; Stoter G; Verweij J; Schellens J H
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
Cancer chemotherapy and pharmacology 1996;38(4):391-4.
1996: van Warmerdam L J; Creemers G J; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens J H; ten Bokkel Huinink W W; Davies B E; Maes R A; Verweij J; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: Verweij J
Mitomycins.
Cancer chemotherapy and biological response modifiers 1996;16():48-56.
1996: Ma J; Verweij J; Planting A S; Kolker H J; Loos W J; de Boer-Dennert M; van der Burg M E; Stoter G; Schellens J H
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
1995: Creemers G J; Wanders J; Gamucci T; Vallentin S; Dirix L Y; Schöffski P; Hudson I; Verweij J
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(8):844-6.
1995: Pronk L C; Stoter G; Verweij J
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Cancer treatment reviews 1995;21(5):463-78.
1995: van Oosterom A T; Verweij J
New drugs for the treatment of sarcomas.
Hematology/oncology clinics of North America 1995;9(4):909-25.
1995: Verweij J
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.
Anti-cancer drugs 1995;6 Suppl 4():19-24.
1995: Schornagel J H; Verweij J; de Mulder P H; Cognetti F; Vermorken J B; Cappelaere P; Armand J P; Wildiers J; de Graeff A; Clavel M
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1649-55.
1995: Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1537-45.
1995: van der Gaast A; Verweij J; Planting A S; Hop W C; Stoter G
Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1720-5.
1995: Bontenbal M; Planting A S; Verweij J; de Wit R; Kruit W H; Stoter G; Klijn J G
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.
Breast cancer research and treatment 1995;34(2):185-9.
1995: Ma J; Verweij J; Planting A S; de Boer-Dennert M; van Ingen H E; van der Burg M E; Stoter G; Schellens J H
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
British journal of cancer 1995;71(3):512-7.
1995: Planting A S; van der Burg M E; de Boer-Dennert M; Stoter G; Verweij J
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(2):190-2.
1995: Wagener D J; Verdonk H E; Dirix L Y; Catimel G; Siegenthaler P; Buitenhuis M; Mathieu-Boué A; Verweij J
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(2):129-32.
1995: de Boer M; de Wit R; Stoter G; Verweij J
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
Journal of cancer research and clinical oncology 1995;121(2):126-7.
1995: van Warmerdam L J; Verweij J; Schellens J H; Rosing H; Davies B E; de Boer-Dennert M; Maes R A; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1995: Verweij J
Topoisomerase I inhibitors and other new cytotoxic drugs.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):828-30.
1995: Verweij J; Catimel G; Sulkes A; Sternberg C; Wolff I; Aamdal S; van Hoesel Q
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 1995;31A Suppl 4():S21-4.
1994: de Wit R; van der Burg M E; van den Gaast A; Logmans A; Stoter G; Verweij J
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):656-7.
1994: Catimel G; Vermorken J B; Clavel M; de Mulder P; Judson I; Sessa C; Piccart M; Bruntsch U; Verweij J; Wanders J
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):543-7.
1994: van Hoesel Q G; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom A T; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):539-42.
1994: Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye S B
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):533-7.
1994: ten Bokkel Huinink W W; Prove A M; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):527-32.
1994: Verweij J; Clavel M; Chevalier B
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):495-505.
1994: Clavel M; Vermorken J B; Cognetti F; Cappelaere P; de Mulder P H; Schornagel J H; Tueni E A; Verweij J; Wildiers J; Clerico M
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):521-6.
1994: Schellens J H; Planting A S; van Acker B A; Loos W J; de Boer-Dennert M; van der Burg M E; Koier I; Krediet R T; Stoter G; Verweij J
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
1994: Ma J; Verweij J; Kolker H J; van Ingen H E; Stoter G; Schellens J H
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
British journal of cancer 1994;69(5):858-62.
1994: Verweij J; Wanders J; Nielsen A L; Pavlidis N; Calabresi F; ten Bokkel Huinink W; Bruntsch U; Piccart M; Franklin H; Kaye S B
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):375-6.
1994: Planting A S; Schellens J H; Goey S H; van der Burg M E; de Boer-Dennert M; Stoter G; Verweij J
Weekly high-dose cisplatin in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):373-4.
1994: van Warmerdam L J; Verweij J; Rosing H; Schellens J H; Maes R A; Beijnen J H
Limited sampling models for topotecan pharmacokinetics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):259-64.
1994: Creemers G J; Lund B; Verweij J
Topoisomerase I inhibitors: topotecan and irenotecan.
Cancer treatment reviews 1994;20(1):73-96.
1994: De Mulder P H; Cappelaere P; Cognetti F; Verweij J; Schornagel J H; Vermorken J B; Kirkpatrick A; Lefebvre J L
A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
Cancer chemotherapy and pharmacology 1994;33(5):438-40.
1994: Pronk L C; Planting A S; Oosterom R; Drogendijk T E; Stoter G; Verweij J
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1019-22.
1994: Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):842-3.
1994: Aamdal S; Wolff I; Kaplan S; Paridaens R; Kerger J; Schachter J; Wanders J; Franklin H R; Verweij J
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1061-4.
1994: Verweij J; Aamdal S; Schellens J; Koier I; Lund B
Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
Oncology research 1994;6(10-11):519-23.
1993: van der Gaast A; Henzen-Logmans S C; Planting A S; Stoter G; Verweij J
Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):789-90.
1993: Vermorken J B; Verweij J; de Mulder P H; Cognetti F; Clavel M; Rodenhuis S; Kirkpatrick A; Snow G B
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):785-8.
1993: Planting A S; van der Burg M E; de Boer-Dennert M; Stoter G; Verweij J
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
British journal of cancer 1993;68(4):789-92.
1993: Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(8):673-8.
1993: Schellens J H; Loos W; Beijnen J H; Stoter G; Verweij J
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.
1993: de Wit R; Kaye S B; Roberts J T; Stoter G; Scott J; Verweij J
Oral piritrexim, an effective treatment for metastatic urothelial cancer.
British journal of cancer 1993;67(2):388-90.
1993: Steward W P; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):15-21.
1993: Steward W P; Vantongelen K; Verweij J; Thomas D; Van Oosterom A T
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?
European journal of cancer (Oxford, England : 1990) 1993;29A(7):943-7.
1993: Steward W P; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
Cancer chemotherapy and pharmacology 1993;31 Suppl 2():S241-4.
1993: Planting A S; Stoter G; Verweij J
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(4):518-9.
1993: Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):208-9.
1992: Schornagel J H; van der Vegt S; Verweij J; de Graeff A; Dullemond-Westland A; van Deijk W A; ten Bokkel Huinink W W
Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(7):549-52.
1992: Kaye S B; Wanders J; Clavel M; Verweij J; Piccart M J; Smyth J F; Ten Bokkel Huinink W W; Wagener D J; Judson I R; Cavalli F
Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(5):406-8.
1992: Planting A S; van der Burg M E; Stoter G; Beranek P; Verweij J
Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1992;4(3):171-3.
1992: Verweij J; van Oosterom A T; Somers R; Santoro A; Rouëssé J; Keizer J; Tursz T; Woll P; Steward W; Buesa J
Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 2():S75-80.
1992: Verweij J; Planting A S; de Boer M; van der Burg M E; Stoter G
Frequent administration of Dabis Maleate, a phase I study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):241-2.
1992: Schornagel J H; Verweij J; de Mulder P H; Cognetti F; Vermorken J B; Cappelaere P; Armand J P; Wildiers J; Clavel M; Kirkpatrick A
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):223-6.
1992: van der Burg M E; Lammes F B; Verweij J
CA 125 in ovarian cancer.
The Netherlands journal of medicine 1992;40(1-2):36-51.
1992: Blackledge G; Steward W P; Verweij J; Mouridsen H; Bramwell V; Schütte J; van Oosterom A; Dombernowsky P; Buesa J; Van Glabekke M
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Seminars in oncology 1992;19(1 Suppl 1):14-8.
1992: Bontenbal M; Planting A S; Rodenburg C J; Dees A; Verweij J; Bartels C C; Alexieva-Figusch J; van Putten W L; Klijn J G
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer.
Breast cancer research and treatment 1992;21(2):133-8.
1992: Somers R; Santoro A; Verweij J; Lucas P; Rouëssé J; Kok T; Casali A; Seynaeve C; Thomas D
Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):855-7.
1992: Verweij J; Planting A; van der Burg M; Stoter G
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Journal of cancer research and clinical oncology 1992;118(8):606-8.
1991: Planting A; Hoff A; van der Burg M; Verweij J; Stoter G
Phase II study of ACNU as first-line treatment in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(10):767-8.
1991: Seynaeve C; De Mulder P H; Verweij J; Gralla R J
Controlling cancer chemotherapy-induced emesis. An update.
Pharmaceutisch weekblad. Scientific edition 1991;13(5):189-97.
1991: Verweij J; Herweijer H; Oosterom R; van der Burg M E; Planting A S; Seynaeve C; Stoter G; Nooter K
A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.
British journal of cancer 1991;64(2):361-4.
1991: Seynaeve C; Verweij J; de Mulder P H
5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
Anti-cancer drugs 1991;2(4):343-55.
1991: Seynaeve C; de Mulder P H; Lane-Allman E; van Liessum P A; Verweij J
The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1991;3(4):199-203.
1991: Buesa J M; Mouridsen H T; van Oosterom A T; Verweij J; Wagener T; Steward W; Poveda A; Vestlev P M; Thomas D; Sylvester R
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(4):307-9.
1991: Rodenburg C J; Nooter K; Herweijer H; Seynaeve C; Oosterom R; Stoter G; Verweij J
Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(4):305-6.
1991: Seynaeve C; De Mulder P H; Verweij J
Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear.
Pharmaceutisch weekblad. Scientific edition 1991;13(1):1-6.
1991: de Wit R; Tesselaar M; Kok T C; Seynaeve C; Rodenburg C J; Verweij J; Helle P A; Stoter G
Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(11):1383-5.
1991: Steward W P; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom A T; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S193-7.
1991: van der Burg M E; Planting A S; Stoter G; McDaniel C; Vecht C J; Verweij J
Phase I study of DABIS maleate given once every 3 weeks.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1635-7.
1990: Dees A; Batenburg P L; Umar H M; Menon R S; Verweij J
Strongyloides stercoralis associated with a bleeding gastric ulcer.
Gut 1990;31(12):1414-5.
1990: De Mulder P H; Seynaeve C; Vermorken J B; van Liessum P A; Mols-Jevdevic S; Allman E L; Beranek P; Verweij J
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Annals of internal medicine 1990;113(11):834-40.
1990: Verweij J; Schornagel J; de Mulder P; Henzen-Logmans S; Cognetti F; Clavel M; Vermorken J
Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.
Cancer 1990;66(9):1910-3.
1990: Verweij J; Pinedo H M
Mitomycin C: mechanism of action, usefulness and limitations.
Anti-cancer drugs 1990;1(1):5-13.
1990: van der Burg M E; Lammes F B; Verweij J
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(4):301-2.
1990: Planting A; Verweij J; Cox P; Pillay M; Stoter G
Radioimmunodetection in rhabdo- and leiomyosarcoma with 111In-anti-myosin monoclonal antibody complex.
Cancer research 1990;50(3 Suppl):955s-957s.
1990: Schornagel J H; Verweij J; de Mulder P H; Wildiers J; Kirkpatrick A; Cognetti F
Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU.
European journal of cancer (Oxford, England : 1990) 1990;26(7):857.
1990: van Liessum P A; Seynaeve C; de Mulder P H; Kaasa S; Lane-Allman E; Beex L V; Verweij J
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.
European journal of cancer (Oxford, England : 1990) 1990;26(6):769-70.
1990: Verweij J; Planting A S; van der Gaast A; Stoter G
Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(1):77-8.
1990: van der Gaast A; Verweij J; Henzen-Logmans S C; Rodenburg C J; Stoter G
Carcinoma of unknown primary: identification of a treatable subset?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(2):119-22.
1989: Blackledge G; van Oosterom A; Mouridsen H T; Bramwell V; Santoro A; Verweij J; Rouëssé J; Somers R; Wagener T; Buesa J
The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1989;1(2):106-9.
1989: Verweij J; van der Burg M E; van Putten W L; Henzen-Logmans S C; Salewski E; Kraemer H P; Stoter G
Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors.
European journal of cancer & clinical oncology 1989;25(4):627-32.
1989: Planting A S; van der Burg M E; Hoff A M; Verweij J; Stoter G
A phase II study of high dose ifosfamide in metastatic colorectal cancer.
European journal of cancer & clinical oncology 1989;25(1):139-40.
1988: Verweij J; Alexieva-Figusch J; de Boer M F; Reichgelt B; Stoter G
Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group.
European journal of cancer & clinical oncology 1988;24(4):795-6.
1988: van der Gaast A; Verweij J; Planting A S; Stoter G
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
European journal of cancer & clinical oncology 1988;24(4):765-8.
1987: Dees A; Verweij J; van Putten W L; Stoter G
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
European journal of cancer & clinical oncology 1987;23(9):1343-7.
1987: Jansen R L; van der Burg M E; Verweij J; Stoter G
Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
European journal of cancer & clinical oncology 1987;23(8):1131-3.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jaap Verweij

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jaap Verweij (preview)

All Publications